Subscribe to Newsletter to get latest insights & analysis in your inbox. Download the ETPharma App and get the Realtime updates and Save your favourite articles. ​The cases ​are among a wave of patent lawsuits ⁠from biotech companies seeking royalties for the technology ​used in the blockbuster vaccines.A Moderna spokesperson said ​that the company would defend itself against BioNTech's case. BioNTech did not immediately respond to a request for comment on the new lawsuit.Spokespeople for Pfizer, which is not directly involved in the lawsuit, also did ‌not immediately comment.mNEXSPIKE is expected to account for 55% of Moderna's COVID vaccine revenue through ​the 2025-26 ​respiratory virus ⁠season, BioNTech's lawsuit said. (Reporting by Blake Brittain in Washington; editing by Barbara Lewis and Deepa Babington)>

Source: Economic Times February 20, 2026 09:08 UTC